Cord blood market segmentation is one of the most important (and least appreciated) parts of analyzing the cord blood banking industry. As the first and only market research firm to track the stem cell industry, BioInformant has collected over 16 years of historical information on the cord blood industry from 2006 to present. This provides a powerful record if past industry dynamics, as well as a robust platform for making future projections. [Read more…]
Cynata’s “Major Breakthrough” in MSC Manufacturing – Unlimited Quantities, Uniform Batches, Single Donor, & Low Cost
For years, it has been clear that mesenchymal stem cells (MSCs) are a leading type of stem cell being investigated for therapeutic applications, as they have the potential to treat a wide range of acute and degenerative diseases. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic.
MSCs are also advantageous over other stem cells types, because they avoid the ethical issues that surround embryonic stem cell research and appear to be immuno-privileged. Importantly, MSCs also well-suited for use in the exponential growth area of 3D printing, because of their unusual capacity to form structural tissues. [Read more…]
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility
-
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases
-
With 300,000 square feet (27,870 square meters), it is the largest dedicated cell-and-gene-therapy manufacturing facility in the world
-
Facility to reach 200 full-time staff by end of 2018 and continue to recruit high-value positions as market demand increases
SanBio’s Regenerative Medicine Product SB623 to Be Manufactured by Hitachi Chemical
March 13, 2018 03:39, TOKYO — SanBio Group and Hitachi Chemical Co., Ltd. (Hitachi Chemical) jointly announced today that, through an agreement with Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS; formerly PCT Cell Therapy Services, LLC), Hitachi Chemical’s US subsidiary that engages in contract manufacturing and development of regenerative medicine products*1, they will manufacture SB623, a proprietary regenerative medicine product under development by SanBio. Under the agreement, late stage clinical products and commercial products of SB623 for the US and Japanese markets will be manufactured using Hitachi Chemical’s global facilities. [Read more…]
Cytori Completes Enrollment for Habeo™ Cell Therapy for Scleroderma and Impaired Hand Function
-
Cytori developing cell therapies that harness the unique attributes of adipose-derived regenerative cells (ADRCs)
-
40 patients enrolled among 5 French centers: Marseille, Montpelier, Rouen, Lyon, and Paris
SAN DIEGO, Jan. 22, 2018 — Cytori Therapeutics, Inc. (NASDAQ:CYTX) announces completion of patient enrollment in SCLERADEC II (NCT02558543), a randomized, double-blind, placebo-controlled, parallel group, multi-center clinical trial intended to study the safety and efficacy of Habeo™ Cell Therapy in up to 40 subjects with impaired hand function due to scleroderma (systemic sclerosis). [Read more…]
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 19
- Next Page »